Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies.
Amezcua L, Mao-Draayer Y, Vargas WS, Farber R, Schaefer S, Branco F, England SM, Belviso N, Lewin JB, Mendoza JP, Shankar SL; ENDORSE Study Investigators. Amezcua L, et al. Among authors: belviso n. Neurol Ther. 2023 Jun;12(3):883-897. doi: 10.1007/s40120-023-00475-8. Epub 2023 Apr 15. Neurol Ther. 2023. PMID: 37061656 Free PMC article.
Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis.
Bove R, Applebee A, Bawden K, Fine C, Shah A, Avila RL, Belviso N, Branco F, Fong K, Lewin JB, Liu J, England SM, Vignos M. Bove R, et al. Among authors: belviso n. Mult Scler Relat Disord. 2024 Aug;88:105738. doi: 10.1016/j.msard.2024.105738. Epub 2024 Jun 20. Mult Scler Relat Disord. 2024. PMID: 38959591 Free article.
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase.
Spelman T, Eichau S, Alroughani R, Ozakbas S, Khoury SJ, Patti F, Kubala Havrdova E, Boz C, Terzi M, Kuhle J, Grammond P, Lechner-Scott J, Gray O, Amato MP, Laureys G, Shaygannejad V, Hyde R, Wang H, Bozin I, Belviso N, Quan C, Zeng F, van der Walt A, Butzkueven H; MSBase Study Group. Spelman T, et al. Among authors: belviso n. Mult Scler J Exp Transl Clin. 2024 May 25;10(2):20552173241247182. doi: 10.1177/20552173241247182. eCollection 2024 Apr-Jun. Mult Scler J Exp Transl Clin. 2024. PMID: 38800132 Free PMC article.
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program.
Salvetti M, Wray S, Nelles G, Belviso N, Kumar A, Koster T, Castro-Borrero W, Vignos M; POP Investigators. Salvetti M, et al. Among authors: belviso n. Mult Scler J Exp Transl Clin. 2024 May 23;10(2):20552173241238632. doi: 10.1177/20552173241238632. eCollection 2024 Apr-Jun. Mult Scler J Exp Transl Clin. 2024. PMID: 38784791 Free PMC article.
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
Fox RJ, Cree BAC, de Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Singh CM, Altincatal A, Belviso N, Avila RL, Ho PR, Su R, Engle R, Sangurdekar D, de Moor C, Fisher E, Kieseier BC, Rudick RA. Fox RJ, et al. Among authors: belviso n. Neurology. 2024 May 14;102(9):e209357. doi: 10.1212/WNL.0000000000209357. Epub 2024 Apr 22. Neurology. 2024. PMID: 38648580 Free PMC article. Clinical Trial.
Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM.
Williams MJ, Amezcua L, Chinea A, Cohan S, Okai A, Okuda DT, Vargas W, Belviso N, Božin I, Jiang X, Lewin JB, Lyons J, Shen C, England SM, Grimes N. Williams MJ, et al. Among authors: belviso n. Neurol Ther. 2023 Oct;12(5):1669-1682. doi: 10.1007/s40120-023-00517-1. Epub 2023 Jun 24. Neurol Ther. 2023. PMID: 37354276 Free PMC article.
Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics.
Hersh CM, Altincatal A, Belviso N, Kapadia S, de Moor C, Rudick R, Williams JR, Miller C, Koulinska I. Hersh CM, et al. Among authors: belviso n. Mult Scler J Exp Transl Clin. 2022 Jan 7;8(1):20552173211069852. doi: 10.1177/20552173211069852. eCollection 2022 Jan-Mar. Mult Scler J Exp Transl Clin. 2022. PMID: 35024161 Free PMC article.
16 results